Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 287-297

  Ingle, Suzanne M ^a   May, Margaret T ^a   Gill, M John ^b   Mugavero, Michael J ^c   Lewden, Charlotte ^d,e   Abgrall, Sophie ^d,f,g   Fätkenheuer, Gerd ^h   Reiss, Peter ⁱ   Saag, Michael S ^c   Manzardo, Christian ^j   Grabar, Sophie ^d,k,l   Bruyand, Mathias ^d   Moore, David ^m   Mocroft, Amanda ⁿ   Sterling, Timothy R ^o   D'Arminio Monforte, Antonella ^p   Hernando, Victoria ^q,r   Teira, Ramon ^s   Guest, Jodie ^t,u   Cavassini, Matthias ^v   Crane, Heidi M ^w   Sterne, Jonathan A C ^a   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c University of Alabama at Birmingham   (United States)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g AVICENNE HOSPITAL   (France)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^k Unité de Biostatistique et Epidémiologie ^*  (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF MILAN   (Italy)

^q CARLOS III INSTITUTE OF HEALTH   (Spain)

^r CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^s HOSPITAL SIERRALLANA   (Spain)

^t HIV Atlanta VA Cohort Study   (United States)

^u ATLANTA VA MEDICAL CENTER   (United States)

^v LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^w UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

antiretroviral therapy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MORTALITY; NORTH AMERICA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; VIRUS LOAD; AGED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; COHORT STUDIES; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; RISK FACTORS; YOUNG ADULT;

EID: 84903941749     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu261     Document Type: Article

References (37)

1. MayM, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
2. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-43.
3. MayMT, Ingle SM. Life expectancy of HIV-positive adults: A review. Sex Health 2011; 8:526-33.
4. Leone S, Gregis G, Quinzan G, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: Analysis of a large urban cohort. Infection 2011; 39:13-20.
5. Galli L, Spagnuolo V, Salpietro S, et al. Mortality of HIV-infected patients with or without cancer: Comparison with the general population in Italy. Antivir Ther 2012; 17:447-58.
6. Aldaz P, Moreno-Iribas C, Egues N, et al. Mortality by causes in HIVinfected adults: Comparison with the general population. BMC Public Health 2011; 11:300.
7. Lohse N, Gerstoft J, Kronborg G, et al. Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: A Danish population-based cohort study. J Acquir Immune Defic Syndr 2011; 57:334-9.
8. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
9. Gill MJ, May M, Lewden C, et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010; 50:1387-96.
10. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virusassociated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118:164-72.
11. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods. AIDS 2012; 26:1311-8.
12. Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012; 55:1228-35.
13. May MT, Ingle SM, Costagliola D, et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol 2013. Advance Access published 18 April 2013. doi: 10.1093/ije/dyt010.
14. The CoDe ("Coding of Death in HIV") Project. Available at: Http://www. cphiv.dk/code/about/tabid/64/default.aspx. Accessed 29 May 2013.
15. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-8.
16. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94:496-509.
18. MayMT, Hogg RS, Justice AC, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics. Int J Epidemiol 2012; 41:1807-20.
19. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: Initial results and evaluation of methodology. Epidemiology 2011; 22:516-23.
20. Roulson J, Benbow EW, Hasleton PS. Dis.crepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-Analysis and review. Histopathology 2005; 47:551-9. (Pubitemid 41775176)
21. Cox JA, Lukande RL, Lucas S, Nelson AM, VanMarck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev 2010; 12:183-94.
22. Kowalska JD, Mocroft A, Ledergerber B, et al. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. HIV Clin Trials 2011; 12:109-17.
23. Kowalska JD, Reekie J, Mocroft A, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: No evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS 2012; 26:315-23.
24. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-30. (Pubitemid 40347381)
25. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100:1896-903.
26. Horvath KJ, Eastman M, Prosser R, Goodroad B, Worthington L. Addressing smoking during medical visits: Patients with human immunodeficiency virus. Am J Prev Med 2012; 43(5 suppl 3): S214-21.
27. Schouten J, Wit FW, Stolte IG, et al. Comorbidity and ageing in HIV-1 infection: The AGEhIV Cohort Study. In: 19th International AIDS Conference, Washington D.C., 2012. Abstract THAB0205.
28. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77. (Pubitemid 33096808)
29. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-6.
30. Moyer VA; US Preventive Service Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159:51-60.
31. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013; 27:563-72.
32. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: The role of 'non-HIV' biomarkers. HIV Med 2010; 11:143-51.
33. Thompson AJ, Locarnini S. Direct-Acting antiviral agents for the treatment of HCV. Antivir Ther 2012; 17(6 pt B): 1105-7.
34. Munteanu DI, Rockstroh J. New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther Adv Infect Dis. 2013; 1:71-80.
35. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study. HIV Med 2011; 12:412-21.
36. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services, 2012. Available at: Http:// aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 12 August 2013.
37. European AIDS Clinical Society Guidelines version 6.1, November 2012. Available at: Http://www.europeanaidsclinicalsociety.org/images/ stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf. Accessed 18 March 2013.